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ABSTRACT
ObjectiveTosynthesisetheliteratureontheeffectsoffish
oil—docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA)—on mortality and arrhythmias and to explore
dose response and formulation effects.
Design Systematic review and meta-analysis.
Data sources Medline, Embase, the Cochrane Library,
PubMed, CINAHL, IPA, Web of Science, Scopus, Pascal,
Allied and Complementary Medicine, Academic OneFile,
ProQuest Dissertations and Theses, Evidence-Based
Complementary Medicine, and LILACS.
Studies reviewed Randomised controlled trials of fish oil
as dietary supplements in humans.
DataextractionTheprimaryoutcomesofinterestwerethe
arrhythmicend pointsof appropriateimplantablecardiac
defibrillator intervention and sudden cardiac death. The
secondary outcomes were all cause mortality and death
from cardiac causes. Subgroup analyses included the
effect of formulations of EPA and DHA on death from
cardiac causes and effects of fish oil in patients with
coronary artery disease or myocardial infarction.
Datasynthesis12studiestotalling32779patientsmetthe
inclusion criteria. A neutral effect was reported in three
studies (n=1148) for appropriate implantable cardiac
defibrillator intervention (odds ratio 0.90, 95% confidence
interval 0.55 to 1.46) and in six studies (n=31111) for
sudden cardiac death (0.81, 0.52 to 1.25). 11 studies
(n=32439 and n=32519) provided data on the effects of
fish oil on all cause mortality (0.92, 0.82 to 1.03) and a
reduction in deaths from cardiac causes (0.80, 0.69 to
0.92). The dose-response relation for DHA and EPA on
reductionindeathsfromcardiaccauseswasnotsignificant.
Conclusions Fish oil supplementation was associated
withasignificantreductionindeathsfromcardiaccauses
but had no effect on arrhythmias or all cause mortality.
Evidence to recommend an optimal formulation of EPA or
DHAtoreducetheseoutcomesisinsufficient.Fishoilsare
a heterogeneous product, and the optimal formulations
for DHA and EPA remain unclear.
INTRODUCTION
An interest in the therapeutic use of n-3 poly-
unsaturated fatty acids (omega 3 fats, or fish oil) to
prevent and treat cardiovascular diseases began after a
report in 1976 showed that the high consumption of
fishoilinInuitlivinginGreenlandwasassociatedwith
adecreasedriskofcardiovasculardisease.
1TheGISSI-
Prevenzione trial
w1 of 11324 patients randomised to a
mixture of the omega 3 fats eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA, 850-882 mg/
day ina ratioof 1.2:1,respectively) orplaceboshowed
a significant reduction in all cause mortality and death
fromcardiovascularcausesover3.5yearsoffollow-up.
These results seemed to be driven by a reduction in
sudden cardiac death, sparking an interest in the
potential antiarrhythmic properties of fish oil. Three
recentrandomisedclinicaltrialslookedatfishoilinthe
prevention of sudden cardiac death in patients with
implantable cardiac defibrillators.
w2-w4 None of these
trials, or a recent systematic review,
2 showed a
beneficial effect of fish oil on patient outcomes. This
may be because of methodological limitations such as
overly optimistic estimates of effect sizes, poor patient
adherencetothetreatmentregimen,andhighlossesto
follow-up (all contributing to reduced study power),
andtheuseofdifferentformulationsoffishoil(content
of EPA and DHA). DHA has been reported to
accumulate preferentially over EPA in the plasma
membrane of cardiac myocytes.
34This might confer a
different effect on stabilising the membrane by chan-
ging its physical, electrical, and chemical properties.
This might also result in DHA having a different
influence on cardiac ion channels. In addition, both
EPA and DHA are known to inhibit sodium channels,
and DHA also inhibits Kv and Kir channels, which are
involved in depolarisation and repolarisation of
cardiac cells. This might result in different anti-
arrhythmic properties for each fatty acid.
5-7 We
evaluated the effect of EPA and DHA on all cause
mortality and deaths from cardiac causes based on the
formulation of these compounds. Previous systematic
reviews are inconclusive as they do not include the
most recent studies.
8 Given the clinical and public
health importance of sudden cardiac death, and the
lack of clear evidence on the benefit of fish oil in this
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tion between fish oil and arrhythmic events.
METHODS
WefollowedtheproceduresoutlinedbytheCochrane
Collaboration for systematic reviews.
9 In November
2006 two librarians (MD and TC) searched Medline
(1966-2006), Embase (1988-2006), the Cochrane
Library, PubMed, CINAHL (1982-October 2006),
IPA (1970-October 2006), Web of Science, Scopus,
Pascal (1987-September 2006), Allied and Comple-
mentary Medicine (1985-October 2006), Academic
OneFile, ProQuest Dissertations and Theses, Evi-
dence-Based ComplementaryMedicine, and LILACS
using relevant subject headings, Chemical Abstracts
Serviceregistrynumbers,andacollectionoftextwords
representingthe conceptsof fishoil and cardiac death:
“Fish oil”, “omega-3 fatty acids”, “docosahexaenoic
acid”, “eicosapentaenoic acid,”“ docosahexanoic
acid”, “eicosapentanoic acid”, “DHA”, “EPA”, “unsa-
turated fatty acid”, “N3 fatty acids”, “omega fatty
acids”, “polyunsaturated”, “PUFA”, “icosapentaenoic
acid”,“suddencardiacdeath”,“cardiacsuddendeath”,
“ventricular tachycardia”, “arrhythmogenic right ven-
tricular dysplasia”, “torsades de pointes”, “ventricular
fibrillation”, “heart arrest”, “myocardial infarction”,
“cardiovascular disease”, “heart disease”, “coronary
disease”, “heart attack”, “heart death”, “heart
arrhythmia”, “heart infarction”, “cardiac death”, and
“coronary artery disease”. The terms were not used in
every resource—for instance, spellings of words
depended on whether American or European data-
baseswerebeingsearched.Nolanguagerestrictionwas
applied. Whenappropriate we explodedsubject head-
ings and truncated terms. The searches in some
databases were limited by intrinsic restrictions of
those resources—for example, maximum counts for
characters. Otherwise, we used strategies as compre-
hensive as possible. To identify additional papers we
reviewed a collection of articles on heart disease and
omega 3 fatty acids from the IBIDS database and
reference lists of included studies. In March 2007 we
updated the search to reduce publication bias as much
as possible.
We included studies that tested fish oil as dietary
supplements in humans in a randomised controlled
trialsetting.Trialswere excludediftheydidnotreport
any of the outcomes of interest, were not randomised,
included pregnant women or children, or lasted less
than three months.
Outcomes, data collection, and quality assessment
Theprimaryoutcomesof interestwere the arrhythmic
end points of appropriate implantable cardiac defi-
brillator intervention (confirmed by electrogram) and
sudden cardiac death. The secondary outcomes were
all cause mortality and death from cardiac causes.
Subgroup analyses included the effect of formulations
of EPA and DHA on deaths from cardiac causes and
effectsoffishoilinpatientswithcoronaryarterydisease
or myocardial infarction.
Search results were reviewed to select potentially
relevant abstracts. Two investigators, blinded to
publicationsourceandauthors’names,independently
reviewed the selected abstracts. A third reviewer acted
as mediator to resolve any discrepancies. The full text
of relevant abstracts was obtained. A data collection
form was created and used by two investigators to
extract information independently and systematically
on the outcomes of interest, inclusion criteria, the risk
of bias, and interventions. To ensure accuracy of this
procedure the two reviewers compared collected data.
A third reviewer acted as mediator for discrepancies.
Tworeviewersindependentlyassessedthequalityof
each study using a form derived from the Jadad
criteria.
10 In addition, we evaluated other criteria
such as concealment of treatment allocation,
11 funding
agencies, and use of intention to treat analysis.
Statistical analysis
Data were entered into 2×2 tables. We used RevMan
4.2.9 (Cochrane, Copenhagen, Denmark) to analyse
results. Data are presented as odds ratios with 95%
confidenceintervals,usingtheDerSimonianandLaird
randomeffectsmodel.Avalueof0.5wasautomatically
insertedbythestatisticalsoftwaretoallowforreporting
of zero events in a category. Agreement between
reviewers was measured using kappa analysis and the
results were reported using the Cohen kappa index.
12
Forevaluationofheterogeneityweusedboththeχ
2test
andthe I
2test.Theztestwasusedtodetermineoverall
effect. Assessment of publication bias was carried out
by generating a funnel plot from the end points that
showed a significant benefit from fish oil.
Dose-response analysis
To evaluate whether a dose-response exists with EPA
or DHA we carried out a meta-regression analysis
using the random effects model for meta-analysis
regression, and analysed the data using STATA
software. For this analysis we used the outcome of
deaths from cardiac causes, as it was the clinical
outcome that was statistically significantly different in
the main analyses.
Titles and abstracts initially found (n=6713)
Papers initially selected for full text review (n=30)
Papers for final analysis (n=12)
Papers not relevant  (n=6683)
Papers initially selected for full text
evaluation and paired quality scoring (n=21)
Papers not fulfilling inclusion criteria (n=9)
Papers excluded after full text review (n=9):
  Duplicate data (n=3)
  Did not evaluate outcomes of interest (n=6)
Fig 1 | Flow of papers through review
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We evaluated the relative risk of a non-cardiovascular
adverse effect occurring in patients who received fish
oil compared with placebo. We also expressed treat-
ment effects and adverse effects using the numbers
needed to treat to reduce one significant clinical event
and numbers needed to harm for an adverse effect.
RESULTS
An initial search retrieved 6713 titles and abstracts,
from which 6683 editorials, reviews, letters, non-
randomised trials, and studies in animals were
excluded. Of the 30 abstracts selected as potentially
relevant for review of the full text, nine papers were
excludedfornotmeetingtheinclusioncriteria,withan
agreementbyκcoefficientof0.92.Therefore21papers
were considered for data collection and evaluated by
two reviewers, with 100% agreement for quality
assessment. After excluding three papers with dupli-
cate data
13-15 and six for not evaluating an outcome of
interest,
16-21 12 studies were included in the final
analysis (fig 1).
w1-w12
Five of the 12 studies scored 5 for methodological
quality on the Jadad scale, four scored 4, two scored 3,
and one scored 2. The table lists the characteristics of
the included studies.
Primary outcomes
Three studies included 1148 patients with implan-
table cardiac defibrillators who received fish oil or
placebo(fig2).Fishoilsupplementationreducedthe
riskofappropriateimplantable cardiacdefibrillator
intervention by a non-significant 10% (odds ratio
0.90, 95% confidence interval 0.55 to1.46). Six
studies, totalling 31111 patients, evaluated the
effect of fish oil on the incidence of sudden cardiac
death (fig 2). A non-significant reduction in sudden
cardiac death was observed (odds ratio 0.81, 0.52 to
1.25).
Secondary outcomes
Death from cardiac causes was evaluated in 11 studies
involving32519patientsandshowedasignificant20%
decrease in events (odds ratio 0.80, 0.69 to 0.92; fig 3).
The funnel plot, however, shows a partially skewed
pattern that suggests some publication bias (fig 4).
Elevenstudiesevaluatedallcausemortalityinatotalof
32439 patients and showed a non-significant 8%
reduction (odds ratio 0.92, 0.82 to 1.03). These results
were driven primarily by two trials: the GISSI-
Prevenzione trial, and the JELIS trial on the effects of
EPA on major coronary events in patients with
hypercholesterolaemia (fig 5).
w1 w5
Characteristics of included studies on omega 3 fats eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Study Population
Treatment group Control group
EPA and DHA (mg/
day) Control Follow-up(months)
Quality
score* No
Mean (SD)
age (years) No
Mean (SD)
age (years)
Brouwer et al
w4 Implantable cardiac
defibrillation
273 60.5 (12.5) 273 62.4 (11.4) 464 and 335 2 gofhigh oleic acid
sunflower oil
12 or until trial
ended (January
2005)
5
Calo et al
w6 After coronary artery bypass
grafting
79 66.2 (8) 81 64.9 (9) 568-588 and 1132-
1176
Conventional
treatment
13
Durrington et
al
w7
Coronary artery disease and
increased triglyceride levels
30 55.2 (7) 29 54.8 (10.2) 880 and 732 Corn oil 6 4
GISSI-Prev
w1 Two weeks after myocardial
infarction
5666 NA 5668 NA 463.6-481.1 and
386.4-400.9
No placebo 42 4
Johansen et
al
w8
Elective percutaneous
coronary angioplasty
250 60.3 (9.3) 250 59.1 (9.3) 2700 and 2340 Corn oil 6 5
Leaf et al
w3 Implantable cardiac
defibrillation
200 65.7 (0.8) 202 65.3 (0.3) 18.2 and 2361 4 g olive oil 12 5
Nilsen et al
w9 First week after myocardial
infarction
150 NA 150 NA 1136-1176 and
2264-2352
Corn oil Up to 24 (median
18)
3
Raitt et al
w2 Implantable cardiac
defibrillation
100 63 (13) 100 62 (13) 756 and 540 Olive oil: 73% oleic
acid, 12% palmitic
acid
24 or to end of July
2003
5
Sacks et al
w10 Percutaneous coronary
angioplasty
31 62 (7) 28 62 (7) 2800 and 1920 Olive oil 28.8 4
Singh et al
w11 Acute myocardial infarction 122 48.5 (6.5) 118 49.2 (7.2) 1080 and 720 100 mg aluminium
hydroxide
12 4
Von Schacky et
al
w12
Percutaneous coronary
angioplasty
111 57.8 (10) 112 58.9 (8.1) 2120 for 3 months,
1060 for 21 months
and 1290 for
3 months, 510 for
21 months
Mixtureoffattyacids
without EPA and
DHA
24 5
JELIS
w5 Primary prevention about
90%, secondary prevention
about 10% with
hypercholesterolaemia
9326 61 (8) 9319 61 (9) 1764 and 0 No placebo 60 or until
November 2004
2
NA=not available.
*Jadad scale.
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response relation between DHA and EPA and death
from cardiac causes.
Asubgroupanalysiswasdoneontheeffectoffishoil
onsuddencardiacdeathanddeathfromcardiaccauses
in patients with coronary artery disease or after
myocardial infarction, including the secondary pre-
vention arm of the JELIS trial.
w5 Four studies that
included 15528 patients showed a 26% reduction
(0.74,0.59to0.92)insuddencardiacdeathwithfishoil
(fig 6). Eight studies with 16390 patients showed a
significant20%reductionindeathsfromcardiaccauses
compared with placebo (0.80, 0.69 to 0.93) in patients
with coronary artery disease or after myocardial
infarction (fig 6).
Two different approaches were used to compare the
safety and efficacy profiles for fish oil to reduce deaths
from cardiac causes. The incidence of adverse effects
was 10.5% in patients who took fish oil compared with
6.7%inthosewhotookplacebo.Patientstakingfishoil
aretherefore56%morelikelytoexperienceanadverse
effect than those taking placebo. However, most of
these effects were described as mild. This corresponds
to a number needed to treat with fish oil to reduce one
deathfromcardiaccausesof189,andanumberneeded
to harm of 26.
Study and  subcategory Fish oil Placebo
No with event/
No in group
Weight 
(%)
Odds ratio
(random) (95% CI)
Odds ratio
(random) (95% CI)
Implantable cardiac defibrillator intervention
  Leaf et al 2005w3
  Raitt et al 2005
w2
  Brouwer et al 2006w4
Total (95% CI)
Total events: 170 (fish oil), 188 (placebo)
Test for heterogeneity: χ2=6.81, df=2, P=0.03, I2=70.6%
Test for overall effect: z=0.43, P=0.67
Sudden cardiac death
  Singh et al 1997w11
  GISSI-Prevenzione 1999w1
  Nilsen et al 2001w9
  Leaf et al 2005
w3
  Raitt et al 2005
w2
  JELIS 2007
w5
Total (95% CI)
Total events: 147 (fish oil), 191 (placebo)
Test for heterogeneity: χ2=6.45, df=5, P=0.26, I
2=22.5%
Test for overall effect: z=0.97, P=0.33
44/200
51/100
75/273
573
2/122
122/5666
0/150
3/200
2/100
18/9326
15 564
66/202
41/100
81/273
575
8/118
164/5658
1/150
1/202
0/100
17/9319
15 547
33.86
26.75
39.39
100.00
6.47
60.77
1.66
3.24
1.83
26.02
100.00
0.58 (0.37 to 0.91)
1.50 (0.86 to 2.62)
0.90 (0.62 to 1.30)
0.90 (0.55 to 1.46)
0.23 (0.05 to 1.10)
0.74 (0.58 to 0.93)
0.33 (0.01 to 8.19)
3.06 (0.32 to 29.68)
5.10 (0.24 to 107.62)
1.06 (0.55 to 2.05)
0.81 (0.52 to 1.25)
0.2 0.5 12 5
Favours fish oil Favours placebo
Fig 2 | Effect of fish oil on appropriate implantable cardiac defibrillator intervention and sudden cardiac death
Study Fish oil Placebo Odds ratio
(random) (95% CI)
Odds ratio
(random) (95% CI)
Weight 
(%)
0.2 0.5 12 5
Favours fish oil Favours control
  Sacks et al 1995w10
  Singh et al 1997w11
  GISSI-Prevenzione 1999
w1
  Johansen et al 1999w8
  Von Shacky et al 1999
w12
  Durrington et al 2001
w7
  Nilsen et al 2001
w9
  Leaf et al 2005
w3
  Raitt et al 2005w2
  Brouwer et al 2006
w4
  JELIS 2007w5
Total (95% CI)
Total events: 360 (fish oil), 446 (placebo)
Test for heterogeneity: χ2=6.90, df=10, P=0.74, I
2=0%
Test for overall effect: z=3.08, P=0.002
0/41
14/122
291/5666
1/250
0/111
0/30
8/150
9/200
2/100
6/273
29/9326
16 269
1/39
26/118
348/5658
3/250
1/112
1/29
8/150
9/202
5/100
13/273
31/9319
  
16 250
0.31 (0.01 to 7.82)
0.46 (0.23 to 0.93)
0.83 (0.70 to 0.97)
0.33 (0.03 to 3.20)
0.33 (0.01 to 8.27)
0.31 (0.01 to 7.96)
1.00 (0.37 to 2.74)
1.01 (0.39 to 2.60)
0.39 (0.07 to 2.05)
0.45 (0.17 to 1.20)
0.93 (0.56 to 1.55)
0.80 (0.69 to 0.92)
0.20
4.10
79.77
0.40
0.20
0.20
2.02
2.29
0.74
2.12
7.96
100.00
No with event/
No in group
Fig 3 | Effect of fish oil on death from cardiac causes
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Our systematic review of randomised trials of fish oil
supplementation showed no beneficial effect on
arrhythmic events or all cause mortality but a
significant reduction in deaths from cardiac causes.
This is in contrast to the results of the GISSI-
Prevenzionetrial,
w1whichsuggestedthatthebeneficial
effect on death was due primarily to a reduction in
sudden cardiac death.
This is the first systematic review attempting to
evaluate whether the protective mechanism of fish oil
supplementationisrelatedtoareductionofarrhythmic
episodes determined either by a reduction in implan-
table cardiac defibrillator interventions or a reduction
in sudden cardiac death. We found a neutral effect on
thesetwooutcomes.Theconfidenceintervalsforthese
outcomes were wide and a beneficial effect up to a 45-
48% relative risk reduction cannot be excluded. Some
heterogeneity was found among the three studies that
assessed implantable cardiac defibrillator intervention
(see fig 2). Also, regardless of the highquality scores of
thesestudies,differencesamongthemweresubstantial,
including dosages of fish oil and important differences
instudypower.Ourdatasupporttherecentanalysisby
Jenkins et al
2 which focused on implantable cardiac
defibrillator interventions only. In light of currently
available evidence the role of fish oil in reducing
arrhythmic events in people at risk still remains to be
elucidated.
Our analysis showed a highly variable effect of fish
oil supplementation on sudden cardiac death, varying
froma48%reductionineventstoa25%increase(fig2).
These results were mainly driven by two studies, the
GISSI-Prevenzione and JELIS trials.
w1 w5 GISSI-Pre-
venzionewasa secondarypreventionstudyin patients
after myocardial infarction with a moderate fish intake
and mainly DHA supplementation,
w1 whereas the
JELIS trial included patients with hypercholesterolae-
mia for both primary and secondary prevention who
had a high fish intake, received statins, and received
only EPA supplementation.
w5 The role and perhaps
interactionofstatinsandfishconsumptionwithfishoil
supplementation need further study.
We observed a significant 20% reduction in deaths
from cardiac causes. This is similar to previous
systematic reviews that included studies of dietary
intake of fish oil either by increased intake or
supplementation,whichshowedasignificantreduction
in cardiovascular events (including strokes). Most of
these events were, however, related mainly to a
reduction in deaths from coronary events with a
reduction in risk ranging from 24% to 36%.
822-24
Experimental studies have proposed that fish oil
helps to stabilise the atherosclerotic plaque through
several mechanisms, which include anti-inflammatory
properties (production of fewer inflammatory prosta-
glandins and leukotrienes), inhibition of lipoprotein
lipase in the atherosclerotic plaque, and selective
uptake of low density lipoprotein cholesterol, inhibi-
tion of transcription factors such as NF-κB gene that is
Odds ratio (fixed)
0.2 0.5 1 25
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Fig 4 | Funnel plot for assessment of publication bias for death
from cardiac causes in 11 included studies reporting data on
this outcome
Study Fish oil Placebo Odds ratio
(random) (95% CI)
Odds ratio
(random) (95% CI)
Weight 
(%)
0.2 0.5 12 5
Favours fish oil Favours control
  Sacks et al 1995
w10
  GISSI-Prevenzione 1999w1
  Johansen et al 1999
w8
  Von Shacky et al 1999
w12
  Durrington et al 2001w7
  Nilsen et al 2001
w9
  Calo et al 2005w6
  Leaf et al 2005
w3
  Raitt et al 2005
w2
  Brouwer et al 2006w4
  JELIS 2007
w5
Total (95% CI)
Total events: 797 (fish oil), 865 (placebo)
Test for heterogeneity: χ2=10.30, df=10, P=0.41, I2=2.9%
Test for overall effect: z=1.48, P=0.14
0/41
472/5666
1/250
1/111
0/30
11/150
1/79
13/200
4/100
8/273
286/9326
16 226
1/39
545/5658
3/250
1/112
1/29
11/150
2/81
12/202
10/100
14/273
265/9319
16 213
0.31 (0.01 to 7.82)
0.85 (0.75 to 0.97)
0.33 (0.03 to 3.20)
1.01 (0.06 to 16.34)
0.31 (0.01 to 7.96)
1.00 (0.42 to 2.38)
0.51 (0.05 to 5.70)
1.10 (0.49 to 2.47)
0.38 (0.11 to 1.24)
0.56 (0.23 to 1.35)
1.08 (0.91 to 1.28)
0.92 (0.82 to 1.03)
0.12
57.08
0.23
0.16
0.11
1.59
0.21
1.83
0.84
1.53
36.30
100.00
No with event/
No in group
Fig 5 | Effect of fish oil on all cause mortality
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matrix metalloproteinases (specifically MMP-9), and
chemokines.
2526Inaddition,fishoilreducestheactivity
of the CD-40 system that plays an important part in
rupture of atherosclerotic plaque through actions on
platelet activation and stimulating NF-κB gene.
27 A
recent clinical study found a reduction of MMP-9 and
sCD4L as well as an increase in plasma levels of
pregnancyassociatedplasmaproteinAinpatientsafter
myocardial infarction randomised to receive two
tablets of 850-882 mg EPA and DHA mixture for one
year.
28 These changes were, however, similar between
thegroupsthatreceivedcornoilorplacebo.Therefore
the potential mechanisms enabling fish oil to reduce
deaths from cardiac causes remain elusive.
We did not find a significant reduction in all cause
mortality, whereas previous reviews showed a signifi-
cant reduction.
822-24 The upper limit of the confidence
interval was only 1.03, which might represent a lack of
power for this end point. We also excluded studies on
dietary supplementation.
Although a wide variety of fish oil products with
various formulations have been studied, we did not
observe a dose-response relation for effect on deaths
from cardiac causes according to dosage of EPA or
DHA. Therefore an ideal formulation for fish oil
supplementation cannot be determined with the
currently available evidence.
We also evaluated the adverse effect profile of fish
oil. The use of fish oil supplements is associated with a
higher prevalence of adverse reactions; these were
mild, however, consisting mainly of diarrhoea or
nausea. In addition, the wide variation in formulation
and dosages among the trials may affect the incidence
of adverse effects observed in our study. The trade-off
for fewer deaths from cardiac causes is that one in 26
patients will develop mostly a mild gastrointestinal
adverse effect. Recently it was reported that the most
common adverse effects in patients with hypertrigly-
ceridaemia who received fish oil 4 g/day compared
with placebo in addition to simvastatin 40 mg/day for
eight weeks were nasopharyngitis (3.3%), diarrhoea
(2.5%), dyspepsia (2.5%), bronchitis, and cystitis; an
increase in liver enzymes was observed in 1.6% of
patients with each adverse event.
29 Therefore it would
beadvisabletoweighthebenefitsandrisksofusingfish
oil in patients with cardiovascular risk factors, espe-
cially those with baseline gastrointestinal disease.
Limitations
The results of this systematic review were driven
primarily by two large, but different trials, GISSI-
PrevenzioneandJELIS,
w1 w5whichtogetheraccounted
for 92% of the patients. Nevertheless, our review was
the first to include the JELIS trial, totalling more than
18000 patients.
w5 Despite our detailed and compre-
hensive search strategy, the funnel plot showed a
skewed pattern suggesting publication bias, whereby
neutral or negative trials may not be published.
Sudden cardiac death in patients with coronary artery disease
Study Fish oil Placebo Odds ratio
(random) (95% CI)
Odds ratio
(random) (95% CI)
Weight 
(%)
0.2 0.5 12 5
Favours fish oil Favours control
  Singh et al 1997w11
  GISSI-Prevenzione 1999w1
  Nilsen et al 2001w9
  JELIS (secondary prevention 2007)w5
Total (95% CI)
Total events: 137 (fish oil), 186 (placebo)
Test for heterogeneity: χ2=3.01, df=3, P=0.39, I
2=0.3%
Test for overall effect: z=2.64, P=0.008
Cardiac death in patients with coronary artery disease
  Sacks et al 1995
w10
  Singh et al 1997w11
  GISSI-Prevenzione 1999w1
  Johansen et al 1999
w8
  Von Shacky et al 1999
w12
  Durrington et al 2001w7
  Nilsen et al 2001w9
  JELIS (secondary prevention 2007)w5
Total (95% CI)
Total events: 332 (fish oil), 409 (placebo)
Test for heterogeneity: χ2=4.31, df=7, P=0.74, I2=0%
Test for overall effect: z=2.90, P=0.004
2/122
122/5666
0/150
13/18
7761
0/41
14/122
291/5666
1/250
0/111
0/30
8/150
18/1823
8193
8/118
164/5658
1/150
13/1841
7767
1/39
26/118
348/5658
3/250
1/112
1/29
8/150
21/1841
8197
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Fig 6 | Effect of fish oil on sudden cardiac death and death from cardiac causes in patients with coronary artery disease
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amounts of EPA and DHA in the formulations among
the studies reviewed, making it difficult to determine
the optimal dosage.
Another limitation in our analysis was the presence
of statistical heterogeneity among the outcomes
measured. Significant heterogeneity (I
2=70.6%) was
found among the implantable cardiac defibrillator
trials,whichmightaffectthevalidityofthisanalysis(see
fig 2). The statistical heterogeneity shown in the forest
plotsfortheotheroutcomesmeasuredinourstudyare,
however, relatively low.
Our analysis of appropriate implantable cardiac
defibrillator intervention included 1148 patients from
secondary prevention trials and showed a non-
significant effect of fish oil that might be a type 2
error. If a new randomised controlled trial using one
formulation of fish oil were designed to evaluate
appropriate implantable cardiac defibrillator inter-
ventions in one year in patients with an implantable
cardiac defibrillator for secondary prevention, assum-
ing that 33% of these patients had an appropriate
implantablecardiacdefibrillatorinterventionperyear,
at least 1600 patients (without including losses to
follow-upordrop-outs)wouldberequiredtoobservea
20%reductionofeventswithan80%power.Therefore
our pooled analysis for this end point should be
considered inconclusive on the basis of small sample
size and noticeable heterogeneity among the trials.
Implications for clinical practice
Based on the best currently available evidence, the
resultsofthissystematicreviewshowabeneficialeffect
of fish oil in reducing deaths from cardiac causes. The
optimaldoseor formulationoffishoilisunknown,but
itseemsreasonabletouseadailyformulationsimilarto
that used in the GISSI-Prevenzione trial, of about
465 mg EPA/386 mg DHA. The effect of fish oil on
arrhythmic events remains inconclusive.
Conclusions
On the basis of data from over 30000 patients, fish oil
supplementation was associated with a significant
reduction in deaths from cardiac causes but had no
significant effect on arrhythmias. Ongoing trials, such
astheOMEGAtrial,
30andfuturestudiesmighthelpto
clarify whether the reduction in deaths from cardiac
causesresultsfromareductionofarrhythmiasorfroma
delay in the progression of coronary artery disease.
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